Clinical practice interviews

Treatment of hypertension: When to start? What is the target? Dr. Franz H. Messerli in an interview with Dr. Roman Jaeschke: part 2

Franz H. Messerli, Roman Jaeschke

Pol Arch Intern Med. 2017, Vol. 127, No. 3: 221-222 / DOI: 10.20452/pamw.3993

Treatment of hypertension: choosing the first‑line treatment. Dr. Franz H. Messerli in an interview with Dr. Roman Jaeschke: part 1

Franz H. Messerli, Roman Jaeschke

Pol Arch Intern Med. 2017, Vol. 127, No. 3: 219-220 / DOI: 10.20452/pamw.3992

Microbiome: fecal transplant in Clostridium difficile and ulcerative colitis. Dr. Paul Moayyedi in an interview with Dr. Roman Jaeschke: part 2

Paul Moayyedi, Roman Jaeschke

Pol Arch Intern Med. 2017, Vol. 127, No. 2: 137-138 / DOI: 10.20452/pamw.3963

Microbiome: the beginning of understanding. Dr. Paul Moayyedi in an interview with Dr. Roman Jaeschke: part 1

Paul Moayyedi, Roman Jaeschke

Pol Arch Intern Med. 2017, Vol. 127, No. 2: 135-136 / DOI: 10.20452/pamw.3961

Cystic fibrosis: past, present, future. Dr. Andreas Freitag in an interview with Dr. Roman Jaeschke

Andreas Freitag, Roman Jaeschke

Pol Arch Intern Med. 2017, Vol. 127, No. 1: 73-75 / DOI: 10.20452/pamw.3922

VTE treatment in 201 6 and future challenges Dr. Mark Crowther in an interview with Dr. Roman Jaeschke: part 3

Mark Crowther, Roman Jaeschke

Pol Arch Intern Med. 2016, Vol. 126, No. 12: 1026-1027 / DOI: 10.20452/pamw.3780

Milestones in VTE treatment. Dr. Mark Crowther in an interview with Dr. Roman Jaeschke: part 2

Mark Crowther, Roman Jaeschke

Pol Arch Intern Med. 2016, Vol. 126, No. 12: 1025-1025 / DOI: 10.20452/pamw.3778

2015 in hematology and thromboembolism. Dr. Mark Crowther in an interview with Dr. Roman Jaeschke: part 1

Mark Crowther, Roman Jaeschke

Pol Arch Intern Med. 2016, Vol. 126, No. 12: 1024-1024 / DOI: 10.20452/pamw.3776

HOPE­‑3, BP treatment, milestones in CV prevention. Dr. Salim Yusuf in an interview with Dr. Akbar Panju and Dr. Roman Jaeschke

Salim Yusuf, Akbar Panju, Roman Jaeschke

Pol Arch Intern Med. 2016, Vol. 126, No. 12: 1033-1035 / DOI: 10.20452/pamw.3765

Treatment of asthma: predicting the future of atopic disease treatment Dr. Paul O’Byrne in an interview with Dr. Roman Jaeschke: part 2

Paul O’Byrne, Roman Jaeschke

Pol Arch Intern Med. 2016, Vol. 126, No. 12: 1031-1032 / DOI: 10.20452/pamw.3763

Treatment of asthma: roles of different classes of drugs Dr. Paul O’Byrne in an interview with Dr. Roman Jaeschke: part 1

Paul O’Byrne, Roman Jaeschke

Pol Arch Intern Med. 2016, Vol. 126, No. 12: 1028-1030 / DOI: 10.20452/pamw.3761

Safety of long‑acting ß2‑agonists: current state of knowledge. Dr. Paul O’Byrne in an interview with Dr. Roman Jaeschke: part 2

Paul O’Byrne, Roman Jaeschke

Pol Arch Intern Med. 2016, Vol. 126, No. 11: 912-913 / DOI: 10.20452/pamw.3669

Safety of long­‑acting β2­‑agonists: a little bit of history. Dr. Paul O’Byrne in an interview with Dr. Roman Jaeschke: part 1

Paul O’Byrne, Roman Jaeschke

Pol Arch Intern Med. 2016, Vol. 126, No. 11: 910-911 / DOI: 10.20452/pamw.3667

Aspirin in prevention of cardiovascular events. Dr. Gordon Guyatt in an interview with Dr. Roman Jaeschke

Gordon Guyatt, Roman Jaeschke

Pol Arch Intern Med. 2016, Vol. 126, No. 11: 909-909 / DOI: 10.20452/pamw.3665

Drugs in diabetes in 2016, changes in endocrinology in 2015. Dr. Hertzel Gerstein in an interview with Dr. Roman Jaeschke

Hertzel Gerstein, Roman Jaeschke

Pol Arch Intern Med. 2016, Vol. 126, No. 11: 907-908 / DOI: 10.20452/pamw.3663

SPRINT trial and blood pressure treatment. Dr. Gordon Guyatt in an interview with Dr. Roman Jaeschke

Gordon Guyatt, Roman Jaeschke

Pol Arch Intern Med. 2016, Vol. 126, No. 10: 806-807 / DOI: 10.20452/pamw.3614

Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes mellitus. Dr. Hertzel Gerstein in an interview with Dr. Roman Jaeschke

Hertzel Gerstein, Roman Jaeschke

Pol Arch Intern Med. 2016, Vol. 126, No. 10: 803-805 / DOI: 10.20452/pamw.3612

Periprocedural risk of bleeding and thrombosis: to bridge or not to bridge. Dr. James Douketis in an interview with Dr. Roman Jaeschke: part 2

James Douketis, Roman Jaeschke

Pol Arch Intern Med. 2016, Vol. 126, No. 10: 801-802 / DOI: 10.20452/pamw.3610

BRIDGE trial. Dr. James Douketis in an interview with Dr. Roman Jaeschke: part 1

James Douketis, Roman Jaeschke

Pol Arch Intern Med. 2016, Vol. 126, No. 10: 798-800 / DOI: 10.20452/pamw.3608

Stress ulcer prophylaxis in critical care: a 2016 perspective Dr. Waleed Alhazzani in an interview with Dr. Roman Jaeschke: part 2

Waleed Alhazzani, Roman Jaeschke

Pol Arch Intern Med. 2016, Vol. 126, No. 10: 796-797 / DOI: 10.20452/pamw.3606

of 2next

Impact Factor 2022

4.8

IC value for 2022

217.18

Ministry of Education and Science score

200
Average times from:
submission to 1st decision, 2 days
submission to first reviews, 24 days
acceptance to online first publication, 5 days
acceptance to final publication, 45 days

Current manuscript acceptance rate: 27%
The journal is co-financed from the state budget under the "Development of scientific journals" program of the Ministry of Education and Science in the years 2022-2024. Read more